Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases.

Welcome to the 7^th Treg-Directed Therapies Summit , the premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights, clinical data, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders, including Abata Therapeutics, Harvard Medical School, Nektar Therapeutics, Parvus Therapeutics, PolTreg, ThyTech and many more!

Whether you are in discovery, navigating the complexities of IND filings, or transitioning to the clinic, this forum provides an unparalleled opportunity to engage with companies and academics at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production, build strategic relationships with investors, pharmaceutical companies and academics, opening doors to future collaborations and partnership opportunities. Featuring two tracks - one focused on Treg Cell Therapies and the other on Treg Modulators - this summit offers a unique opportunity to gain knowledge from the latest engineering innovations and clinical advancements.